Pharmaceutical production, like other sectors of the economy, is for the most part relocated to India and China, and this raises certain questions: what quality control for these drugs, how to protect against a possible shortage in the event of an epidemic?
More and more pharmaceutical companies are outsourcing the production of their drugs. 80% of the medicines consumed in France are manufactured in China or India. This globalization poses two problems: the quality of molecules and the difficulties of supply. Pictures of drug manufacturing and pharmaceutical laboratories in France, India and China.
India and China supply 80% of the raw material to pharmaceutical factories that manufacture medicines sold in France. Patrick MAISON, from the National Drug Safety Agency, points out the repercussions that this can have in the event of a manufacturing problem.
India and China supply 80% of the raw material to pharmaceutical factories that manufacture medicines sold in France. On the plateau Anne-Charline Lambard develops the consequences of this dependence: shortage of stock in case of defective quality (discontinuation of production lines) or export speculation.